[
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7814",
   "LocalID": "c8a8caba-2251-491c-8758-14da15b51065",
   "VariationID": 7814,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43403,
   "Description": "PTEN c.469G>T (p.E157X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 8071972)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863471.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7815",
   "LocalID": "67ade3e6-3038-4022-903b-9caf929577ba",
   "VariationID": 7815,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.510T>A (p.S170R) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PS3: Phosphatase activity <50% of wild type (PMID 17942903, PMID 10866302, PMID 9256433, PMID 21828076) PM2: Absent in large sequenced populations (PMID 27535533). PP1: Co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed. (PMID 17526800, PMID 9241266) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 17526800)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863480.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7816",
   "LocalID": "4ed5aa0a-d183-4c08-b6f6-23ffb9904a78",
   "VariationID": 7816,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.368A>G (p.H123R) PTEN c.368A>G (p.H123R) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel. PM2: Absent in large sequenced populations. (PMID 27535533) PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10234502) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863477.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7823",
   "LocalID": "47291ab6-b17d-4e14-9acd-faae6fe9ec1e",
   "VariationID": 7823,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.586delC (p.H196Tfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863475.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7824",
   "LocalID": "ebef4811-dc36-4625-bd07-ea516d1cad7e",
   "VariationID": 7824,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.534_535delTAinsAT (p.Y178X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032, PMID 23335809)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863472.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7828",
   "LocalID": "4284ff17-816f-4321-a0b3-e3baeb0afc95",
   "VariationID": 7828,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.766G>T (p.E256X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 9832032) PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 9832032)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863478.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7829",
   "LocalID": "844aa93c-ba66-4b09-825a-8e5e0fb0a775",
   "VariationID": 7829,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.389G>A (p.R130Q) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PM6_VS: At least four assumed de novo observations in a patient with the disease and no family history. (PMID 22595938, PMID 22327138, internal laboratory contributor(s) SCV000222111.11) PS3: Phosphatase activity <50% of wild type (PMID 10866302) PS4: Probands with phenotype specificity score of 4-15.5 (PMID 26798346, PMID 17526801, PMID 23335809, PMID 22266152) PM1: Located at a residue within a catalytic motif as defined by the ClinGen PTEN Expert Panel. PM2: Absent in large sequenced populations (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840465.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7831",
   "LocalID": "3026a8af-72dd-459e-be90-922c578fc8f6",
   "VariationID": 7831,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.564T>A (p.Y188X) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863469.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7834",
   "LocalID": "d7cc25c0-43b3-408c-8e19-6aab8d40a4f1",
   "VariationID": 7834,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.40dupA (p.R14Kfs) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 10777358) PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 10777358)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863473.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN7844",
   "LocalID": "1c091a56-7fdb-41a4-9573-e48254ef08b7",
   "VariationID": 7844,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.-764G>A (NC_000010.10:g.89623462G>A) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840498.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN41682",
   "LocalID": "0340272b-ab4c-4672-94b8-40e0525d8eda",
   "VariationID": 41682,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.235G>A (p.A79T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Allele frequency of 0.0045 (0.45%, 9/1984 alleles) in the GME variome. (PMID 27428751) BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000222198.12) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840467.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN92808",
   "LocalID": "d1c7275d-fc3f-4feb-b749-4a6562cbc2d9",
   "VariationID": 92808,
   "ClinicalSignificance": "Benign",
   "DateLastEvaluated": 42683,
   "Description": "PTEN c.-9C>G (NC_000010.10:g.89624218C>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BA1: Allele frequency of 0.048 (4.8%, 903/18,870 alleles) in the East Asian subpopulation of the gnomAD cohort. (PMID 27535533)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840463.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN92810",
   "LocalID": "30a41c35-daf4-47cc-b83c-ccf0c557f631",
   "VariationID": 92810,
   "ClinicalSignificance": "Benign",
   "DateLastEvaluated": 42627,
   "Description": "PTEN c.1026+32T>G (IVS8+32T>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BA1: Allele frequency of 0.374 (37.4%, 102,771/274,696 alleles) in the gnomAD cohort. (PMID 27535533)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840460.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN92813",
   "LocalID": "4fa0530f-2999-441d-b303-9451e343e97b",
   "VariationID": 92813,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 42683,
   "Description": "PTEN c.132C>T (p.G44=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Allele frequency of 0.167 (1.67%, 463/276,792 alleles) in the gnomAD cohort. (PMID 27535533) BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000212700.3) BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000212700.3) BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840470.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN92816",
   "LocalID": "9b41938e-76e1-469c-a782-0fabdaceb60c",
   "VariationID": 92816,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43087,
   "Description": "PTEN c.209+4_209+7delAGTA (IVS3+4_IVS3+7delAGTA) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PS3: RNA, mini-gene, or other assay shows impact on splicing. (PMID 28677221) PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (Internal laboratory contributor(s)) PM2: Absent in large sequenced populations (PMID 27535533). PP1_M: Co-segregation with disease in multiple affected family members, with 5 or 6 meioses observed. (Internal laboratory contributor(s)) PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 28677221, internal laboratory contributor(s) SCV000273868.4)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840483.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN92818",
   "LocalID": "e0072965-9b20-4fa8-bfab-2ec93223849b",
   "VariationID": 92818,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 42718,
   "Description": "PTEN c.254-39G>T (IVS4-39G>T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Allele frequency of 0.0064 (0.64%, 112/17,490 alleles) in the South Asian subpopulation of the gnomAD cohort. (PMID 27535533) BP4: Intronic variant where at least 2 out of 3 in silico models predict no splicing impact. BP7: Variant is intronic and at or beyond +7/-21, nucleotide is not conserved, and no splicing impact is predicted.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840477.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN92822",
   "LocalID": "9c15b246-ef9f-4f55-a246-126b49710717",
   "VariationID": 92822,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.395G>A (p.G132D) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PM2: Absent in large sequenced populations (PMID 27535533). PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000279163.8) PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 25288137, PMID 23335809, PMID 23470840, internal laboratory contributor(s)) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863470.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN92827",
   "LocalID": "e8d81f24-56b8-4bfb-82c1-e3c4bb305db9",
   "VariationID": 92827,
   "ClinicalSignificance": "Benign",
   "DateLastEvaluated": 42627,
   "Description": "PTEN c.79+35C>T (IVS1+35C>T) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Allele frequency of 0.00178 (1.78%, 492/277,200 alleles) in the gnomAD cohort. (PMID 27535533) BS3: Intronic variant with RNA, mini-gene, or other splicing assay demonstrating no splicing impact. (PMID 17636424)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840499.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN92829",
   "LocalID": "742d7bc7-fc1a-47ac-b7fb-3be400cfe09f",
   "VariationID": 92829,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 43369,
   "Description": "PTEN c.801+23G>A (IVS7+23G>A) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Allele frequency of 0.0024 (0.24%, 58/24,016 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533) BP4: Intronic variant where at least 2 out of 3 in silico models predict no splicing impact.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840490.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN127661",
   "LocalID": "b49fa554-1a60-419c-8931-6cdc5564285c",
   "VariationID": 127661,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.-1142C>T (NC_000010.10:g.89623084C>T) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). BS1: Allele frequency of 0.0049 (0.49%, 8/1622 alleles) in the East Asian subpopulation of the gnomAD cohort. (PMID 27535533) BP2: Observed in trans with a pathogenic or likely pathogenic PTEN variant, at least three observations in cis and/or phase unknown with different pathogenic/likely pathogenic PTEN variants. (Internal laboratory contributors SCV000187279.1, SCV000149465.6)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863474.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN127662",
   "LocalID": "8c50af60-fe53-4c9b-b60a-3735d21c8645",
   "VariationID": 127662,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43047,
   "Description": "PTEN c.-1170C>T (NC_000010.10: g.89623056C>T) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000149466.6, SCV000184146.1)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840482.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN127667",
   "LocalID": "eb4d52da-5b73-477e-9890-d8c613ea7ae5",
   "VariationID": 127667,
   "ClinicalSignificance": "Benign",
   "DateLastEvaluated": 42888,
   "Description": "PTEN c.-1311T>C (NC_000010.10:g.89622915T>C) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BA1: Allele frequency of 0.0142 (1.42%, 23/1618 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840491.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN127674",
   "LocalID": "400140b3-b081-46b3-8b10-03492bb903d0",
   "VariationID": 127674,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.-798G>C (NC_000010.10:g.89623428G>C) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). No criteria currently apply to this variant.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863481.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN127687",
   "LocalID": "ba4a2bab-161e-445b-a38c-7ef4639e08a9",
   "VariationID": 127687,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43047,
   "Description": "PTEN c.1052_1054delTAG (p.V351del) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PM2: Absent in large sequenced populations (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840493.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN138835",
   "LocalID": "044a4a6a-4939-4e73-8b9d-ff941b58e27d",
   "VariationID": 138835,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 42627,
   "Description": "PTEN c.1104T>C (p.D368=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Allele frequency of 0.0057 (0.57%, 130/22,966 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533) BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact. BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840471.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN138836",
   "LocalID": "b70739f7-4e4b-4678-8c1b-43aa0547db91",
   "VariationID": 138836,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 42683,
   "Description": "PTEN c.-1026C>A (NC_000010.10:g.89623200C>A) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Allele frequency of 0.0056 (0.56%, 173/30,898 alleles) in the gnomAD cohort. (PMID 27535533) BS2_P: Meets criteria for BS2 (observed in the homozygous state in at least one healthy or PHTS-unaffected individual) but BS1 is also applied. (Internal laboratory contributor(s) SCV000171228.5) BP5: Variant found in multiple cases with alternate molecular basis for disease. (Internal laboratory contributor(s) SCV000171228.5)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840478.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN138837",
   "LocalID": "b7b13ffa-c41f-4c0e-9db4-dd26cede580d",
   "VariationID": 138837,
   "ClinicalSignificance": "Benign",
   "DateLastEvaluated": 42627,
   "Description": "PTEN c.-903G>A (NC_000010.10:g.89623323G>A) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BA1: Allele frequency of 0.011 (1.1%, 343/30,808 alleles) in the gnomAD cohort. (PMID 27535533)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840480.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN141485",
   "LocalID": "e71dcbfe-0aed-4400-9ea2-5ec0ef78a666",
   "VariationID": 141485,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.493-2A>G (IVS5-2A>G) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM6_S: Two probands with presumed de novo occurrence (maternity/paternity not confirmed) in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000222118.9) PM2: Absent in large sequenced populations.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840458.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN141654",
   "LocalID": "2b40684d-92f4-40ce-8062-ffd5a0278fbd",
   "VariationID": 141654,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.50_51delAA (p.Q17RfsX26) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 20223021)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840481.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN142220",
   "LocalID": "58b7be5a-c98e-4344-9f4f-cff2dd70911d",
   "VariationID": 142220,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.520T>A (p.Y174N) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PS3: Phosphatase activity <50% of wild type (PMID 10866302) PM2: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863476.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN142269",
   "LocalID": "835a14e6-4a41-47df-a1ff-271c872adf39",
   "VariationID": 142269,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.737C>T (p.P246L) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PS2_VS: At least two proven OR one proven plus two assumed de novo observations in a patient with the disease and no family history. (PMID 23934111, internal laboratory contributor(s) SCV000222227.10) PS4: Probands with phenotype specificity score of 4-15.5. (PMID 24375884, PMID 10076877, PMID 22261759, PMID 23934111, internal laboratory contributor(s) SCV000222227.10) PM2: Absent in large sequenced populations. (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840469.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN142423",
   "LocalID": "0b5afc39-258a-4c7d-8a60-f765e5c2eaf2",
   "VariationID": 142423,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.802-2A>T (IVS7-2A>T) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (Internal laboratory contributor(s), SCV000222230.9)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840462.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN142681",
   "LocalID": "742e08c9-7bda-4006-95f1-22f34ec0d9e1",
   "VariationID": 142681,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43047,
   "Description": "PTEN c.304_306dupAAA (p.K102_P103insK) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PM2: Absent in large sequenced populations (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840472.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN183722",
   "LocalID": "9a0535ed-2b90-4309-917f-cbcce2549f2a",
   "VariationID": 183722,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.1026+1G>A (IVS8+1G>A) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4) (PMID 28677221). PM2: Absent in large sequenced populations (PMID 27535533). PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 28677221, internal laboratory contributor(s) SCV000212764.4)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840497.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN184104",
   "LocalID": "5ae8d67a-b184-476c-878e-aef6ec246a56",
   "VariationID": 184104,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43087,
   "Description": "PTEN c.78C>T (p.T26=) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533). BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840494.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN184505",
   "LocalID": "e5e35031-cdfe-44ec-ad5e-0f3892c0a7b1",
   "VariationID": 184505,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 42718,
   "Description": "PTEN c.75G>A (p.L25=) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840466.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN185213",
   "LocalID": "bfdfbf81-6f26-43f8-aa4b-bbb17ebaf54a",
   "VariationID": 185213,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.964A>T (p.K322X) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840475.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN185989",
   "LocalID": "049d3e03-b5ad-4a47-92e9-ee077179049a",
   "VariationID": 185989,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43047,
   "Description": "PTEN c.209+3A>T (IVS3+3A>T) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PM2: Absent in large sequenced populations (PMID 27535533). PP3: At least 2 out of 3 in silico models predict a splicing impact.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840485.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN187590",
   "LocalID": "8c8c1292-baf8-4fcd-abbf-e22a7793a5dd",
   "VariationID": 187590,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.165-1G>A (IVS2-1G>A) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840484.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN187657",
   "LocalID": "f890d81d-90ed-4411-a0fd-a89669dd616a",
   "VariationID": 187657,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.892C>T (p.Q298X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 23470840)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840489.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN187673",
   "LocalID": "2353f24f-8466-46ea-838d-a36a749f6a49",
   "VariationID": 187673,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43047,
   "Description": "PTEN c.1171C>T (p.P391S) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PM2: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840495.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189406",
   "LocalID": "11de4e4a-dc77-4323-92c5-151d4868419d",
   "VariationID": 189406,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.407G>A (p.C136Y) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000222113.9) PS3: Phosphatase activity <50% of wild-type OR RNA, mini-gene, or other assay shows impact on splicing. (PMID 10866302) PM2: Absent in large sequenced populations (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PS4_P: Probands with specificity score of 1-1.5. (PMID 9735393, internal laboratory contributor(s) SCV000222113.9)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840468.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189411",
   "LocalID": "276b536d-e9cf-488e-a7bf-d2d8d0b119b6",
   "VariationID": 189411,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.511C>T (p.Q171X) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PM6: Assumed de novo, but without confirmation of paternity and maternity in a patient with the disease and no family history. (PMID 22595938) PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 17043057, PMID 22595938)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840464.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189424",
   "LocalID": "e5c0aa16-de66-441e-9ef7-cda008c2cef7",
   "VariationID": 189424,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43196,
   "Description": "PTEN c.*10delT (NC_000010.10:g.89725239delT) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the \"PTEN ACMG Specifications Summary\" document (assertion method column). PM2: Absent in large sequenced populations (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000863479.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189425",
   "LocalID": "a81bf7b8-305b-4704-bf65-95e6aa54b5ba",
   "VariationID": 189425,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 42718,
   "Description": "PTEN c.165-13_165-10delGTTT (IVS2-13_IVS2-10delGTTT) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BS1: Allele frequency of 0.0049 (0.49%, 112/22,776 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533) BP4: Intronic variant where at least 2 out of 3 in silico models predict no splicing impact.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840473.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189426",
   "LocalID": "53c09c9e-b77c-4949-8aef-58bcb3346e87",
   "VariationID": 189426,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 42718,
   "Description": "PTEN c.360A>C (p.A120=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact. BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840492.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189441",
   "LocalID": "e41ad782-4c9c-4ae6-ba02-ec2e11c967fc",
   "VariationID": 189441,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.987_990delTAAA (p.N329KfsX14) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID 10232405)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840476.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189462",
   "LocalID": "2f607d68-ce7c-4110-9640-98a0992a2d02",
   "VariationID": 189462,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.80-1G>C (IVS1-1G>C) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840486.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189500",
   "LocalID": "8f2c1cdc-0442-4dc1-ace0-ee811465348e",
   "VariationID": 189500,
   "ClinicalSignificance": "Pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.517C>T (p.R173C) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PS2_VS: At least two proven OR one proven plus two assumed de novo observations in a patient with the disease and no family history. (PMID 17526800, PMID 22628360, internal laboratory contributor(s) SCV000222220.10) PS3: Phosphatase activity <50% of wild type. (PMID 10866302) PM2: Absent in large sequenced populations (PMID 27535533). PS4_M: Probands with phenotype specificity score of 2-3.5. (PMID 22628360, PMID 17526800, PMID 17526801) PP1: Co-segregation with disease in multiple affected family members, with 3 or 4 meioses observed. (PMID 22628360) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840496.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN189520",
   "LocalID": "271c91d3-d627-42bf-86bc-ba9a7f7f2189",
   "VariationID": 189520,
   "ClinicalSignificance": "Benign",
   "DateLastEvaluated": 42627,
   "Description": "PTEN c.-1059C>G (NC_000010.10:g.89623167C>G) meets criteria to be classified as benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BA1: Allele frequency of 0.0138 (1.38%, 120/8698 alleles) in the African subpopulation of the gnomAD cohort. (PMID 27535533)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840479.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN220007",
   "LocalID": "3905138e-990e-4b30-b0aa-96ad556248ac",
   "VariationID": 220007,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43369,
   "Description": "PTEN c.521A>G (p.Y174C) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000602123.1) PM2: Absent in large sequenced populations (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (Internal laboratory contributor(s) SCV000602123.1)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840459.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN231916",
   "LocalID": "4f6345e3-25b1-48cd-9697-1a5624715071",
   "VariationID": 231916,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.103A>G (p.M35V) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (Internal laboratory contributor(s) SCV000275912.5) PM2: Absent in large sequenced populations (PMID 27535533). PS4_M: Probands with phenotype specificity score of 2-3.5. (Internal laboratory contributor(s) SCV000565444.4, SCV000275912.5) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840461.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN233415",
   "LocalID": "747804f8-133a-4807-9f7e-4c8798e82ee5",
   "VariationID": 233415,
   "ClinicalSignificance": "Likely benign",
   "DateLastEvaluated": 42655,
   "Description": "PTEN c.18A>G (p.L6=) meets criteria to be classified as likely benign for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). BP4: Synonymous variant where at least 2 out of 3 in silico models predict no splicing impact. BP7: Variant is synonymous (silent), nucleotide is not conserved, and no splicing impact is predicted.",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840488.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN404140",
   "LocalID": "d8470abc-cd84-4dd7-aa9d-def2c9c878aa",
   "VariationID": 404140,
   "ClinicalSignificance": "Likely pathogenic",
   "DateLastEvaluated": 43026,
   "Description": "PTEN c.801+1delG (IVS7+1delG) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PVS1: Null variant predicted to result in nonsense-mediated decay or causing truncation/frameshift at or 5' to c.1121 (NM_000314.4). PM2: Absent in large sequenced populations (PMID 27535533).",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840487.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 },
 {
   "SubmitterAbbr": "PTEN",
   "Lookup": "PTEN404147",
   "LocalID": "9b8faad8-e78a-4d2f-8805-210367466752",
   "VariationID": 404147,
   "ClinicalSignificance": "Uncertain significance",
   "DateLastEvaluated": 43103,
   "Description": "PTEN c.44G>A (p.R15K) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (Mester et al. 2018; manuscript in preparation). Please see a summary of the rules and criteria codes in the 'PTEN ACMG Specifications Summary' document (assertion method column). PM2: Absent in large sequenced populations (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PS3_P: Abnormal in vitro cellular assay or transgenic model with phenotype different from wild type that does not meet PS3. (PMID 25875300)",
   "SubmittedPhenotypeInfo": "Orphanet:ORPHA306498",
   "ReportedPhenotypeInfo": "C1959582:PTEN hamartoma tumor syndrome",
   "ReviewStatus": "reviewed by expert panel",
   "CollectionMethod": "curation",
   "OriginCounts": "germline:na",
   "Submitter": "ClinGen PTEN Variant Curation Expert Panel",
   "SCV": "SCV000840474.1",
   "SubmittedGeneSymbol": "PTEN",
   "ExplanationOfInterpretation": "-"
 }
]